首页> 外文OA文献 >Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer

【2h】

Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer

机译：Capeox加入西司昔单抗治疗作为延长RAS / BRAF / PIK3CA野生型先进或转移结直肠癌患者的一线治疗的疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Shigeyoshi Iwamoto; Hiromichi Maeda; Shoichi Hazama; Koji Oba; Naoko Okayama; Yutaka Suehiro; Takahiro Yamasaki; Nobuaki Suzuki; Hiroaki Nagano; Junichi Sakamoto; Hideyuki Mishima; Naoki Nagata;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer [J] . Journal of Cancer . 2018,第22期

机译：Capeox加入西司昔单抗治疗作为延长RAS / BRAF / PIK3CA野生型先进或转移结直肠癌患者的一线治疗的疗效
2. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10 [J] . Kienle Dirk L., Dietrich Daniel, Ribi Karin, Journal of geriatric oncology . 2019,第2期

机译：西妥昔单抗单药治疗和西妥昔单抗加上股票素作为老年患者的一线治疗，患者和BRAF野生型转移性结肠直肠癌。多中心第二期试验SAKK 41/10的结果
3. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS / BRAF metastatic colorectal cancer: The FLEET study [J] . Hitoshi Soda, Hiromichi Maeda, Junichi Hasegawa, BMC Cancer . 2015,第1期

机译：FOLFOX或两周一次的XELOX和Erbitux（cetuximab）作为野生型KRAS / BRAF转移性结直肠癌患者的一线治疗的多中心II期研究：FLEET研究
4. Isolation of Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer Using Label-Free Microfluidic Technology for Enumeration and Detection of KRAS, BRAF, PIK3CA Mutation [C] . Haiyan Emily Liu, Evelyn Kidess-Sigal, Melanie Triboulet, International Molecular Medicine Tri-Conference. . 2016

机译：使用无标记微流体技术分离转移性结肠直肠癌患者的循环肿瘤细胞进行募准和检测KRA，BRAF，PIK3CA突变
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer [O] . Shigeyoshi Iwamoto, Hiromichi Maeda, Shoichi Hazama, 2018

机译：CapeOX联合西妥昔单抗治疗扩展型RAS / BRAF / PIK3CA野生型晚期或转移性结直肠癌患者的一线治疗的疗效
7. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study [O] . J. Sastre, P. García-Alfonso, J.M. Viéitez, 2021

机译：BRAF和PIK3CA突变对RAS野生型转移性结直肠癌和<3基线循环肿瘤细胞患者的一线治疗患者的疗效对FOFIRI PLUS BEVACIZUMAB或CETUXIMAB的影响：随机期IIVisnú-2研究

Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer

著录项

相似文献

相关主题

期刊订阅